Scenario:
Please read this scenario prior to answering the Question
You are serving as the Lead Architect for an enterprise architecture project team within a leading medical
device manufacturer that specializes in miniature devices. The latest product under development is a tiny
wireless device that can be implanted in the brain and can deliver a precise electric shock when the wearable
Pain Control Unit (PCU) detects an increase in stress induced by the onset of a migraine headache.
This technology will be a breakthrough in the treatment of this condition, and several competitors are striving to
be the first to introduce a product into the market. However, all of them must demonstrate the effectiveness and
safety of their products in a set of clinical trials that will satisfy the regulatory requirements of the countries in
the target markets.
The Enterprise Architecture group within the company has been engaged in an architecture development
project to create a secure networked collaboration system that will allow researchers at its product development
laboratories worldwide to share information about their independent clinical trials.
The Enterprise Architecture group is a mature organization that has been utilizing TOGAF for several years.
They use the TOGAF 9 ADM with extensions required to support current good manufacturing practices and
good laboratory practices in their target markets. Due to the highly sensitive nature of the information that is
managed, special care was taken to ensure that each architecture domain included an examination of the
security and privacy issues that are relevant for each domain. A corresponding Security Architecture has been
defined.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture activity. She
has stated that the changes to the enterprise architecture for the new system will need to be rolled out on a
geographic basis that will minimize disruptions to ongoing clinical trials. The work will need to be done in stages
and rolled out in geographical regions.
Refer to the Scenario
You have been asked to recommend the approach to identify the work packages that will be included in the
Transition Architecture(s).
Based on TOGAF 9, which of the following is the best answer?

A.
Determine the set of Solution Building Blocks required by identifying which Solution Building Blocks need tobe developed and which need to be procured. Eliminate any duplicate building blocks. Group the remaining
Solution Building Blocks together to create the work packages using a CRUD matrix. Rank the work
packages in terms of cost and select the most cost-effective options for inclusion in a series of Transition
Architectures. Schedule the roll out of the work packages to be sequential across the geographic regions.

B.
Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated Gaps, Solutions
and Dependencies Matrix. For each gap, identify a proposed solution and classify it as new development,
purchased solution, or based on an existing product. Group similar solutions together to form work
packages. Identify dependencies between work packages factoring in the clinical trial schedules. Regroup
the packages into a set of Capability Increments scheduled into a series of Transition Architectures.

C.
Group the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix into a
set of work packages. Using the matrix as a planning tool, regroup the work packages to account for
dependencies. Sequence the work packages into the Capability Increments needed to achieve the Target
Architecture. Schedule the rollout one region at a time. Document the progression of the enterprise
architecture using a state evolution table.

D.
Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For each gap classify
whether the solution is either a new envelopment, purchased solution, or based on an existing product.
Group the similar solutions together to define the work packages. Regroup the work packages into a set of
Capability Increments to transition to the Target Architecture taking into account the schedule for clinical
trials.